Insider Buying: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Acquires 10,000 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director Bernhardt G. Zeiher bought 10,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, March 20th. The shares were acquired at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $37,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Price Performance

AMLX traded down $0.22 during trading hours on Friday, hitting $3.66. 437,209 shares of the stock were exchanged, compared to its average volume of 1,376,916. The stock has a market cap of $323.84 million, a price-to-earnings ratio of -0.96 and a beta of -0.51. The stock has a 50-day simple moving average of $3.55 and a 200-day simple moving average of $4.01. Amylyx Pharmaceuticals, Inc. has a 12 month low of $1.58 and a 12 month high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. Sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $7.33.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. lifted its holdings in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after purchasing an additional 4,883 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at $45,000. Alpine Global Management LLC acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at $45,000. RPO LLC bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $46,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $53,000. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.